瑞舒伐他汀钙联合二甲双胍通过调控葡萄糖转运蛋白4表达发挥对糖尿病大鼠肾脏的保护作用研究

doi:10.12114/j.issn.1007-9572.2022.0039

中国全科医学 ›› 2022, Vol. 25 ›› Issue (18): 2291-2296.DOI: 10.12114/j.issn.1007-9572.2022.0039

所属专题：内分泌代谢性疾病最新文章合集；泌尿系统疾病最新文章合集

瑞舒伐他汀钙联合二甲双胍通过调控葡萄糖转运蛋白4表达发挥对糖尿病大鼠肾脏的保护作用研究

尚葛础¹, 王潇永¹, 高燕²^,^*()

1.250014　山东省济南市，山东中医药大学第一临床医学院
2.250012　山东省济南市，中国人民解放军联勤保障部队第九六〇医院全科医学科

收稿日期:2021-12-17 修回日期:2022-01-26 出版日期:2022-06-20 发布日期:2022-02-24
通讯作者: 高燕
尚葛础，王潇永，高燕.瑞舒伐他汀钙联合二甲双胍通过调控葡萄糖转运蛋白4表达发挥对糖尿病大鼠肾脏的保护作用研究[J].中国全科医学，2022，25（18）：2291-2296. [www.chinagp.net]
作者贡献：尚葛础提出研究思路及主要研究指标，负责研究的实施、统计分析、论文撰写与修改、后期审查；王潇永负责数据整理、数据录入、统计分析、图片整理；高燕负责研究的设计、研究质量控制、指导论文撰写及论文内容审校。
基金资助:
2014年解放军总后勤部保健专项课题(14BJZ27); 2015年解放军总后勤部保健专项课题(15BJZ07)

Rosuvastatin Calcium with Metformin Improves Kidney Function in a Rat Model of Diabetes by Regulating the Expression of Glucose Transporter 4

Gechu SHANG¹, Xiaoyong WANG¹, Yan GAO²^,^*()

1. First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250014, China
2. General Practice Department, 960 Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army, Jinan 250012, China

Received:2021-12-17 Revised:2022-01-26 Published:2022-06-20 Online:2022-02-24
Contact: Yan GAO
About author:
SHANG G C, WANG X Y, GAO Y. Rosuvastatin calcium with metformin improves kidney function in a rat model of diabetes by regulating the expression of glucose transporter 4[J]. Chinese General Practice, 2022, 25 (18) : 2291-2296.

分享到

摘要/Abstract

摘要： 背景瑞舒伐他汀钙联合二甲双胍对糖尿病肾损伤具有保护作用，然而其机制尚不十分明确。目的探讨瑞舒伐他汀钙联合二甲双胍在链脲佐菌素（STZ）诱导的2型糖尿病（T2DM）大鼠肾损伤中的保护作用及机制。方法于2021年7—10月将40只清洁级Wistar大鼠随机分为对照组（C组）、二甲双胍组（M组）、二甲双胍+瑞舒伐他汀钙低剂量组（M+RL组）和二甲双胍+瑞舒伐他汀钙高剂量组（M+RH组），每组各10只。M组、M+RL组、M+RH组大鼠腹腔注射STZ，建立T2DM模型。各组药物灌胃：C组：10 mg·kg-1·d-1 0.9%氯化钠溶液；M组：二甲双胍（200 mg·kg-1·d-1）；M+RL组：二甲双胍（200 mg·kg-1·d-1）混悬液+瑞舒伐他汀钙（0.42 mg·kg-1·d-1）；M+RH组：二甲双胍（200 mg·kg-1·d-1）混悬液+瑞舒伐他汀钙（0.83 mg·kg-1·d-1）。干预6周后处死大鼠，并留取血液及肾脏组织标本。以苏木素-伊红（HE）染色、高碘酸-无色品红（PAS）染色、Masson染色观察各组大鼠肾组织损伤程度；以实时荧光定量聚合酶链式反应（PCR）检测各组大鼠肾脏组织葡萄糖转运蛋白4（GLUT4）mRNA的表达情况；以Western-blotting法检测各组大鼠肾脏组织GLUT4蛋白的表达情况。结果与C组相比，M组、M+RL组、M+RH组大鼠肾小球结构均出现明显损伤，伴有炎性细胞浸润及间质纤维化。M组、M+RL组、M+RH组大鼠肾脏组织GLUT4 mRNA表达水平均低于C组，M组、M+RL组大鼠肾脏组织GLUT4蛋白表达水平均低于C组，M+RL组、M+RH组大鼠肾脏组织GLUT4 mRNA、GLUT4蛋白表达水平均高于M组，M+RH组大鼠肾脏组织GLUT4 mRNA、GLUT4蛋白表达水平高于M+RL组（P<0.05）。结论瑞舒伐他汀钙联合二甲双胍可减轻T2DM大鼠肾小球及肾小管炎性细胞浸润，缓解肾小球基底膜增厚、肾小管空泡变性及肾间质纤维化进程，增加GLUT4 mRNA与GLUT4蛋白表达，且高剂量瑞舒伐他汀钙效果优于低剂量瑞舒伐他汀钙。提示瑞舒伐他汀钙联合二甲双胍可能通过调控GLUT4 mRNA与蛋白的表达，实现对T2DM大鼠肾脏的保护作用，其肾脏保护作用可随瑞舒伐他汀钙剂量增加而增强。

关键词: 糖尿病, 2型, 大鼠, 肾保护, 肾疾病, 瑞舒伐他汀钙, 二甲双胍, 葡萄糖转运蛋白4

Abstract:

Background

Rosuvastatin calcium with metformin improves diabetic renal injury, but the mechanism is not yet fully understood.

Objective

To explore the mechanism of action of rosuvastatin calcium with metformin improving renal injury in a rat model of streptozotocin (STZ) -induced type 2 diabetes mellitus (T2DM) .

Methods

Forty clean grade Wistar rats were equally randomized into a control group (group C) , a metformin group (group M) , a metformin+low-dose rosuvastatin calcium group (group M+RL) , and a metformin+high-dose rosuvastatin calcium group (group M+RH) from July to October 2021. T2DM model was established for three groups (except for group C) using intraperitoneal injection of STZ. Then drug was administered by intragastric administration to the groups as follows: equal amount of 0.9% sodium chloride solution for group C, metformin (200 mg·kg^-1·d^-1) for group M, metformin (200 mg·kg^-1·d^-1) suspension+rosuvastatin calcium (0.42 mg·kg^-1·d^-1) for group M+RL, and metformin (200 mg·kg^-1·d^-1) suspension+rosuvastatin calcium (0.83 mg·kg^-1·d^-1) for group M+RH. Rats were sacrificed after 6 weeks of intervention, while their blood and kidney tissues were collected. The extent of injury of kidney tissues was observed under light microscope after being stained with H&E, and was analyzed using Image-Pro Plus 6.0 after being stained with periodic-acid schiff, and Masson's trichrome, respectively. The expression of glucose transporter 4 (GLUT4) mRNA in the renal tissue was measured by real-time polymerase chain reaction (PCR) , and the protein levels of GLUT4 were detected by Western-blotting.

Results

Compared with group C, the glomerulus of rats in other three groups showed significant structural damage, accompanied by inflammatory cell infiltration and interstitial fibrosis. Moreover, mRNA expression levels of GLUT4 in these groups were significantly lowered (P<0.05) . Furthermore, the protein levels of GLUT4 in groups M and M+RL were lowered notably (P<0.05) . The mRNA and protein expression levels of GLUT4 in group M+RL or M+RH were higher than those of group M (P<0.05) . In addition, the mRNA and protein expression levels of GLUT4 in M+RH group were higher than those in M+RL group (P<0.05) .

Conclusion

Rosuvastatin calcium with metformin could reduce inflammatory cell infiltration in glomerular and tubular, alleviate glomerular basement membrane thickening and tubular vacuolar degeneration, delay the interstitial fibrosis development, and increase GLUT4 mRNA and GLUT4 protein expression in STZ-induced T2DM rats. Moreover, higher dose of rosuvastatin calcium showed better effect. Our study indicated that rosuvastatin calcium combined with metformin may achieve a renoprotective effect by regulating the expression of GLUT4 mRNA and protein in T2DM rats, and this effect may be enhanced with the increase in the dose of rosuvastatin calcium.

Key words: Diabetes mellitus, type 2, Rats, Renal protection, Kidney diseases, Rosuvastatin calcium, Metformin, Glucose transporter 4

尚葛础,王潇永,高燕. 瑞舒伐他汀钙联合二甲双胍通过调控葡萄糖转运蛋白4表达发挥对糖尿病大鼠肾脏的保护作用研究[J]. 中国全科医学, 2022, 25(18): 2291-2296. DOI: 10.12114/j.issn.1007-9572.2022.0039.
Gechu SHANG,Xiaoyong WANG,Yan GAO. Rosuvastatin Calcium with Metformin Improves Kidney Function in a Rat Model of Diabetes by Regulating the Expression of Glucose Transporter 4[J]. Chinese General Practice, 2022, 25(18): 2291-2296. DOI: 10.12114/j.issn.1007-9572.2022.0039.

图/表 5

表1 PCR扩增引物序列

Table 1 PCR amplified β-actin and glucose transporter 4 sequences

引物	序列（5'-3'）	长度（bp）
β-actin	上游：TGCTATGTTGCCCTAGACTTCG	240
	下游：GTTGGCATAGAGGTCTTTACGG
GLUT4	上游：CCTGCCCGAAAGAGTCTAAAGC	316
	下游：CTAAGAGCACCGAGACCAACG

图1 各组大鼠肾脏组织形态学变化（HE染色）注：C组=对照组，M组=二甲双胍组，M+RL组=瑞舒伐他汀钙低剂量+二甲双胍组，M+RH组=瑞舒伐他汀钙高剂量+二甲双胍组

Figure 1 Morphological changes of kidney tissues stained with H&E in control rats and streptozotocin-induced T2DM rats

图2 各组大鼠肾脏组织形态学变化（PAS染色）

Figure 2 Morphological changes of kidney tissues stained with periodic-acid schiff in control rats and streptozotocin-induced T2DM rats

图3 各组大鼠肾脏组织形态学变化（Masson染色）

Figure 3 Morphological changes of kidney tissues stained with Masson's trichrome in control rats and streptozotocin-induced T2DM rats

图4 各组大鼠GLUT4蛋白相对表达量注：GLUT4=葡萄糖转运蛋白4

Figure 4 The relative expression levels of glucose transporter 4 protein in control rats and streptozotocin-induced T2DM rats

参考文献 20

[1]	中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2017年版）[J]. 中国实用内科杂志，2018，38(4):292-344. DOI：10.19538/j.nk2018040108.
[2]	MA G, BI S T. Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease[J]. Exp Ther Med，2019，17(1):332-336. DOI：10.3892/etm.2018.6923.
[3]	LEE J, HWANG Y C, LEE W J，et al. Comparison of the efficacy and safety of rosuvastatin/ezetimibe combination therapy and rosuvastatin monotherapy on lipoprotein in patients with type 2 diabetes：multicenter randomized controlled study[J]. Diabetes Ther，2020，11(4):859-871. DOI：10.1007/s13300-020-00778-1.
[4]	BAE J C, MIN K W, KIM Y H，et al. Efficacy and safety of fixed-dose combination therapy with gemigliptin （50 mg） and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia （BALANCE）：a multicentre，randomized，double-blind，controlled，phase 3 trial[J]. Diabetes Obes Metab，2019，21(1):103-111. DOI：10.1111/dom.13491.
[5]	SONG A N, ZHANG C, MENG X F. Mechanism and application of metformin in kidney diseases：an update[J]. Biomed Pharmacother，2021，138:111454. DOI：10.1016/j.biopha.2021.111454.
[6]	章超，曹玲玲，沈冬梅，等. 瑞舒伐他汀联合二甲双胍对2型糖尿病患者血糖、血脂、炎症因子及胰岛素抵抗的影响[J]. 中国现代医生，2020，58(24):124-126,130.
[7]	OGURTSOVA K, DA ROCHA FERNANDES J D, HUANG Y，et al. IDF Diabetes Atlas：global estimates for the prevalence of diabetes for 2015 and 2040[J]. Diabetes Res Clin Pract，2017，128:40-50. DOI：10.1016/j.diabres.2017.03.024.
[8]	HONG T P, SU Q, LI X Y，et al. Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology[J]. Diabetes Metab Res Rev，2021，37(4):e3416. DOI：10.1002/dmrr.3416.
[9]	NOMANI H, MOHAMMADPOUR A H, REINER Z，et al. Statin therapy in post-operative atrial fibrillation：focus on the anti-inflammatory effects[J]. J Cardiovasc Dev Dis，2021，8(3):24. DOI：10.3390/jcdd8030024.
[10]	KANNO M, NAKAYAMA M, ZHU W J，et al. Rosuvastatin pretreatment suppresses distant organ injury following unilateral renal ischemia-reperfusion in hypertensive Dahl salt-sensitive rats[J]. Nephrology （Carlton），2018，23(11):1046-1054. DOI：10.1111/nep.13169.
[11]	DAI Y N, HUANG J L, ZENG L H，et al. Comparison of the preventive efficacy of rosuvastatin versus atorvastatin in post-contrast acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention[J]. Biomedecine Pharmacother，2020，128:110336. DOI：10.1016/j.biopha.2020.110336.
[12]	MORRISON M C, YAKALA G K, LIANG W，et al. Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice：a possible role for adiponectin and miR-21? [J]. Sci Rep，2017，7(1):2915. DOI：10.1038/s41598-017-02444-2.
[13]	DU X G, RUAN X Z. Lipid metabolism disorder and renal fibrosis[J]. Adv Exp Med Biol，2019，1165:525-541. DOI：10.1007/978-981-13-8871-2_26.
[14]	TOSO A, LEONCINI M, MAIOLI M，et al. A prospective，randomized，open-label trial of atorvastatin versus rosuvastatin in the prevention of contrast-induced acute kidney injury，worsened renal function at 30 days，and clinical events after acute coronary angiography：the PRATO-ACS-2 study[J]. Cardiorenal Med，2020，10(5):288-301. DOI：10.1159/000506857.
[15]	JIANG Z H, ZHANG J, LU Y A. Protective effects and mechanisms of rosuvastatin on acute kidney injury induced by contrast media in rats[J]. Int J Nephrol，2020，2020:3490641. DOI：10.1155/2020/3490641.
[16]	ABDEEN A, ABOUBAKR M, ELGAZZAR D，et al. Rosuvastatin attenuates piroxicam-mediated gastric ulceration and hepato-renal toxicity in rats[J]. Biomed Pharmacother，2019，110:895-905. DOI：10.1016/j.biopha.2018.11.004.
[17]	NARESH S, BITLA A R, RAO P V L N S，et al. Efficacy of oral rosuvastatin intervention on HDL and its associated proteins in men with type 2 diabetes mellitus[J]. Endocrine，2021，71(1):76-86. DOI：10.1007/s12020-020-02472-5.
[18]	BAO S, WANG X, CHO S B，et al. Agriophyllum oligosaccharides ameliorate diabetic insulin resistance through INS-R/IRS/Glut4-mediated insulin pathway in db/db mice and min 6 cells[J]. Front Pharmacol，2021，12:656220. DOI：10.3389/fphar.2021.656220.
[19]	LIN J L, CHEN P S, LIN H W，et al. Real-world analyses of the safety outcome among a general population treated with statins：an Asian population-based study[J]. J Atheroscler Thromb，2021. DOI：10.5551/jat.63076.
[20]	TAGUCHI I, IIMURO S, IWATA H，et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease （REAL-CAD）：a randomized superiority trial[J]. Circulation，2018，137(19):1997-2009. DOI：10.1161/CIRCULATIONAHA.117.032615.

瑞舒伐他汀钙联合二甲双胍通过调控葡萄糖转运蛋白4表达发挥对糖尿病大鼠肾脏的保护作用研究

Rosuvastatin Calcium with Metformin Improves Kidney Function in a Rat Model of Diabetes by Regulating the Expression of Glucose Transporter 4

RichHTML

PDF

PDF (英文版)

可视化

摘要/Abstract

引用本文

使用本文

图/表 5

参考文献 20

相关文章 15

编辑推荐

Metrics

留言

[1]	姚裕忠, 马晓骏, 宋懽, 钟瑜. 基于"全专精准管理"的糖尿病"1358模式"对社区糖尿病患者的管理效果研究[J]. 中国全科医学, 2023, 26(34): 4308-4314.
[2]	李殿江, 潘恩春, 孙中明, 文进博, 王苗苗, 武鸣, 沈冲. 社区2型糖尿病患者临床惰性现状及其影响因素分析[J]. 中国全科医学, 2023, 26(34): 4296-4301.
[3]	林恺, 姚弥, 陈章, 纪欣鑫, 林润琪, 陈永松, Sim MOIRA. 2型糖尿病治疗负担的概念框架及应对方式：基于视频记录分析[J]. 中国全科医学, 2023, 26(34): 4302-4307.
[4]	杨慧, 胡汝为, 刘汝青, 卢俊峰, 吴兢兰. 糖尿病患者社区卫生服务体验与血糖控制效果的关系研究[J]. 中国全科医学, 2023, 26(34): 4290-4295.
[5]	张娟, 李海芬, 李小曼, 姚苗, 马惠珍, 马强. 糖尿病足溃疡复发风险预测模型的构建：基于Logistic回归和支持向量机及BP神经网络模型[J]. 中国全科医学, 2023, 26(32): 4013-4019.
[6]	程经纬, 乔军军, 尹振, 胡俊鹏, 王庆贺, 柳杨青, 汪艳芳. 《2022 ISPAD临床实践共识指南：儿童和青少年糖尿病患儿运动》解读[J]. 中国全科医学, 2023, 26(30): 3719-3724.
[7]	韦雨柔, 田佳庆, 肖方骏, 何宪顺, 詹芝玮, 魏腾飞, 林天烨, 何敏聪, 魏秋实. 活血通络胶囊对激素性股骨头坏死大鼠肠道菌群影响的研究[J]. 中国全科医学, 2023, 26(29): 3674-3682.
[8]	周小琦, 刘新会, 张微, 李长风, 严亚琼. 老年人丙氨酸氨基转移酶和天冬氨酸氨基转移酶/丙氨酸氨基转移酶与2型糖尿病及代谢综合征的相关性研究[J]. 中国全科医学, 2023, 26(29): 3645-3649.
[9]	赵晓华, 杜林, 高胜男, 蒋子云. 老年糖尿病合并多发肌肉深部脓肿一例报道并文献分析[J]. 中国全科医学, 2023, 26(29): 3715-3718.
[10]	程晓冉, 张笑天, 李明月, 程昊哲, 汤皓晴, 郑汇娴, 张柏松, 刘晓云. 医防融合背景下慢性病随访对高血压和糖尿病患者健康行为及血压/血糖控制的影响研究[J]. 中国全科医学, 2023, 26(28): 3482-3488.
[11]	罗丹, 徐晶晶, 王玉冰, 李明子, FORBES Angus. 心理韧性导向的青少年1型糖尿病患者结构化治疗与教育课程的开发及初步实践[J]. 中国全科医学, 2023, 26(27): 3423-3429.
[12]	董亚楠, 姜晓锐, 王凯, 宗传冲, 林国栋, 李香卿, 林春晓, 迟俊涛. 改良胫骨横向骨搬运技术治疗Wagner 3~4级糖尿病足患者的效果研究[J]. 中国全科医学, 2023, 26(27): 3411-3416.
[13]	卢作维, 曹宏伟, 刘涛, 张娜娜, 陈艳艳, 史勤利, 刘向阳, 王琼, 赖敬波, 李晓苗. 2型糖尿病患者微量白蛋白尿进展至大量白蛋白尿的风险预测模型研究[J]. 中国全科医学, 2023, 26(26): 3259-3268.
[14]	陈伦文, 周阳, 闫国栋, 沈怡, 孙晨, 蔡婉丽, 褚敏捷, 肖静. 2型糖尿病的恶性肿瘤风险：一项基于人群的前瞻性研究[J]. 中国全科医学, 2023, 26(26): 3238-3245.
[15]	费思杰, 张强, 刘方方, 白璐, 孙彩红, 信彩凤. 糖化血红蛋白变异性与2型糖尿病合并射血分数保留心力衰竭患者新发心房颤动的关系研究[J]. 中国全科医学, 2023, 26(26): 3246-3251.